Hosted on MSN1mon
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE trial of the allosteric activator of beta-glucocerebrosidase (GCase), BIA 28 ...
Nature1mon
Pfizer stakes a claim in plant cell–made biopharmaceuticals
It acquired rights to taligurase alfa, a form of the enzyme glucocerebrosidase in development for the treatment of Gaucher's disease, from Protalix Biotherapeutics in Carmiel, Israel. Protalix has ...